In the newest installment of her Dumb Blonde podcast, Bunnie Xo revealed that she's started taking a medication called ...

Kezar Life Sciences, Inc. (KZR) announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) ...

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...

In the chart below, we highlight the unlikely scenarios needed to ... Lilly have set the bar for efficacy and side effect ...

The phase IIa study enrolled 243 people with obesity and metabolic syndrome, who were equally randomized into four treatment ...

Global GLP-1 Analogues Market is valued at approximately USD 35.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 33% over the forecast period 2024-2032. Read the ...

Last month, Eli Lilly announced it would reduce the cost of the lowest dose of its drug Zepbound to around $400 a month. It also launched its own telehealth company, LillyDirect. Readdy ...

If anything, the four-week supply of the 2.5 mg Zepbound single-dose vial at $399 (self-pay) is not too far from HIMS' compounded GLP-1 injectables from $199 monthly (based on a 12-month plan).

Wegovy, Zepbound and other cutting-edge weight-loss ... warnings this year about compounded semaglutide, which has caused dosing errors that resulted in severe nausea, vomiting, hypoglycemia ...

Eli Lilly and Company ’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...